Skip to content
Open in App
Ipsen logo

Ipsen

web2

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of...

Symbol · 0MH6
Company profile

About

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

MM

Marc M. P. de Garidel

Non-Executive Chairman

Company leadership profile.

DL

David Loew

MD, CEO & Director

Company leadership profile.

AF

Antoine Flochel

Vice Chairman

Company leadership profile.

MA

Margaret A. Liu

Independent Director

Company leadership profile.

PW

Piet Wigerinck

Independent Director

Company leadership profile.

CB

Catherine-Annick Bradley

Independent Director

Company leadership profile.

AB

Anne Beaufour

Director

Company leadership profile.

CX

Carol Xueref

Director

Company leadership profile.

PB

Philippe Bonhomme

Director

Company leadership profile.

MO

Michèle Ollier

Director

Company leadership profile.

LD

Laetitia Ducroquet

Employees Representative Director

Company leadership profile.

NB

Naomi Binoche

Employee Representative Director

Company leadership profile.

PT

Pascal Touchon

Independent Director

Company leadership profile.

PG

Peter Guenter

Director

Company leadership profile.

Expert coverage

1 expert evaluated Ipsen.

Orbitrum research

Experts evaluating Ipsen

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment